Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer

Liang Dong ^1,2, Cong Hu ¹, Zehua Ma ^1,3

¹Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
²The Brady Urological Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
³Department of Urology, Guizhou Provincial People's Hospital, Guiyang, 550001, China.
⁴Department of Laboratory Medicine & Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Nanfang Hospital Southern Medical University, Guangzhou, 510515, China.
⁵Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
⁶Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
⁷Department of Urology, University of Michigan, Ann Arbor, MI, 48109, USA.
⁸Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. uroxuewei@163.com.
⁹Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Pudong New Area, Shanghai, 200127, China. uroxuewei@163.com.
¹⁰The Brady Urological Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA. kpienta1@jhmi.edu.

⁰Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.

Medical Oncology (Northwood, London, England) +

|

June 5, 2024

View abstract on PubMed

Summary

Urinary extracellular vesicles (EVs) contain miR-126-3p, a potential biomarker for predicting lymph node invasion (LNI) in high-risk prostate cancer (HRPCa) patients. This finding aids in early detection and treatment planning for prostate cancer.

Area Of Science

Urology
Molecular Biology
Biomarkers

Background

Prostate cancer (PCa) management requires accurate prediction of lymph node invasion (LNI).
Extracellular vesicles (EVs) are emerging as promising sources for non-invasive biomarkers.
Identifying reliable biomarkers for high-risk prostate cancer (HRPCa) is crucial for treatment stratification.

Purpose Of The Study

To investigate urinary and plasma extracellular vesicles (EVs) as potential biomarkers for predicting lymph node invasion (LNI) in patients with high-risk prostate cancer (HRPCa).

Main Methods

Prospective collection of plasma and urine samples from 45 PCa patients and 5 benign prostatic hyperplasia (BPH) patients.
Small RNA sequencing of EVs to identify microRNAs (miRNAs).
Validation of candidate miRNAs in low-risk prostate cancer (LRPCa) and BPH cohorts.

Main Results

Four and three miRNA species were elevated in urinary and plasma EVs of PCa patients, respectively.
miR-126-3p was significantly more abundant in urinary EVs of HRPCa patients with LNI compared to those without.
Urinary EV miR-126-3p levels were significantly higher in HRPCa patients compared to LRPCa and BPH patients.

Conclusions

Urinary extracellular vesicles (EVs)-derived miR-126-3p shows potential as a biomarker for predicting lymph node invasion (LNI) in high-risk prostate cancer (HRPCa).
This finding may facilitate improved diagnostic strategies and personalized treatment approaches for prostate cancer.

Keywords:

Extracellular vesicles Lymph node invasion MicroRNAs Prostate cancer